Cingulate Inc. - Common Stock (NQ:CING)

4.750 -0.010 (-0.21%)

Delayed Quote Updated: 4:00 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cingulate Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Why Matrix Service Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket ↗

September 12, 2023

Gainers AgileThought, Inc. (NASDAQ: AGIL) shares rose 72.5% to $0.2160 in pre-market trading after declining 12% on Monday.

Via Benzinga

Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

September 11, 2023

Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study...

Via Benzinga

Why Are Cingulate Shares Trading Higher Today? ↗

July 11, 2023

Cingulate Inc (NASDAQ: CING) announced topline results from its Phase 3 adult trial of its lead candidate, CTx-1301 (dexmethylphenidate) for attention-deficit/

Via Benzinga

ADHD-Focused Cingulate Prices Public Offering, Shares Detailed Pivotal Trial Data ↗

September 11, 2023

Cingulate Inc (NASDAQ: CING) shares are trading lower after the company priced its $4-million public offering at around 58 cents per share

Via Benzinga

Why Tenon Medical Shares Are Trading Lower By 34%; Here Are 20 Stocks Moving Premarket ↗

September 11, 2023

Gainers

Via Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session ↗

September 08, 2023

Via Benzinga

Why Mitek Systems Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket ↗

September 06, 2023

Gainers Marin Software Incorporated (NASDAQ: MRIN) rose 32.8% to $0.5698 in pre-market trading after the company reported HubSpot integration.

Via Benzinga

Cingulate Announces Presentation of Full Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD at Psych Congress 2023

September 05, 2023

Data Accepted as Finalist for First Annual Poster Awards

From Cingulate Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

August 17, 2023

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 15, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

August 14, 2023

Via Benzinga

Cingulate Inc. Reports Second Quarter 2023 Financial Results and Provides Clinical and Business Update

August 14, 2023

From Cingulate Inc.

Via GlobeNewswire

Why Celestica Shares Are Trading Higher By Over 42%; Here Are 20 Stocks Moving Premarket ↗

July 27, 2023

Gainers Celestica Inc. (NYSE: CLS) shares surged 42.2% to $23.40 in pre-market trading after the company announced better-than-expected second-quarter results.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

July 25, 2023

On Tuesday, 56 companies set new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 20, 2023

Via Benzinga

Why Lucid Group Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

July 12, 2023

Gainers Healthcare Triangle, Inc. (NASDAQ: HCTI) shares climbed 171.2% to $8.84 as the company launched initiative to prevent ransomware attacks in the $35 billion healthcare data market.

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

July 12, 2023

Via Benzinga

Why ImmuCell Are Trading Higher; Here Are 20 Stocks Moving Premarket ↗

July 12, 2023

Gainers Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) shares surged 131.6% to $4.03 in pre-market trading after gaining 15% on Tuesday.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

July 12, 2023

It's time to start off Wednesday with an overview of all the biggest pre-market stock movers worth watching this morning!

Via InvestorPlace

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

July 11, 2023

Via Benzinga

Cingulate Announces Positive Top-Line Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD

July 11, 2023

Results Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and Duration

From Cingulate Inc.

Via GlobeNewswire

Cingulate Successfully Manufactures Clinical Supply – Initiation of Pediatric Phase 3 Studies to Commence in July and August

June 29, 2023

Announcement Confirms Cingulate on Track with Development and Regulatory Milestones

From Cingulate Inc.

Via GlobeNewswire

Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

June 20, 2023

Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740.

Via Benzinga

Cingulate Completes Phase 3 Adult Trial of CTx-1301 (dexmethylphenidate) for ADHD

June 08, 2023

From Cingulate Inc.

Via GlobeNewswire

Cingulate to Present at 13th Annual LD Micro Invitational

May 25, 2023

From Cingulate Inc.

Via GlobeNewswire

Partnership By Biotech Firm Could Be Big News For The Commercialization Of Its Innovative ADHD Drug Candidate ↗

May 18, 2023

Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ: CING), and Tim Moore, Senior VP of Biotech of Indegene, were recently guests on Benzinga’s All Access.

Via Benzinga

Cingulate, Indegene to Participate in Benzinga All Live Access Event

May 12, 2023

From Cingulate Inc.

Via GlobeNewswire

Cingulate Inc. Reports First Quarter 2023 Financial Results and Provides Clinical and Business Update

May 10, 2023

From Cingulate Inc.

Via GlobeNewswire

Cingulate Announces Successful Transfer of CTx-1301 (dexmethylphenidate) Proprietary PTR™ Manufacturing Processes to Societal CDMO

May 03, 2023

Scalable Supply of CTx-1301 Ready to be Produced with Cingulate on Track to Meet Previously Announced Clinical Timelines for Phase 3 Trial Program

From Cingulate Inc.

Via GlobeNewswire

Cingulate: This Novel Drug Technology May Soon Relieve A Patient's "Pill-Burden" ↗

April 20, 2023

Shane Schaffer, Chairman & CEO of Cingulate (NASDAQ: CING), was recently a guest on Benzinga’s All-Access.

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.